Composition transferred through nose and brain containing milnacipran

A technology of milnacipran and a composition, which is applied in the field of transnasal-brain transfer composition, can solve the problems of no central selectivity, peripheral adverse reactions and the like

Inactive Publication Date: 2008-11-12
SHANGHAI INST OF PHARMA IND
View PDF4 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

According to the mechanism of action of milnacipran, it can be speculated that the main reason for these problems is that the existing milnacipran preparations have no central selectivity, and only a small amount of the drug enters the brain after entering the systemic circulatory system, resulting in many peripheral adverse events. response, and takes longer to take effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition transferred through nose and brain containing milnacipran
  • Composition transferred through nose and brain containing milnacipran

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0082] Prepare milnacipran nasal drops according to the following ratio:

[0083] Milnacipran

[0084] Preparation method: Take 800ml of deionized water, weigh the prescribed amount of milnacipran, sodium chloride, benzalkonium chloride, sodium carboxymethylcellulose, and disodium edetate, stir and heat to dissolve them completely , after cooling, add deionized water to settle to 1000ml, and adjust the pH to 7 with 0.1mol / L hydrochloric acid to obtain milnacipran nasal drops.

Embodiment 2

[0086] Prepare milnacipran nasal drops according to the following ratio:

[0087] Milnacipran

[0088] Preparation method: take 800ml of deionized water, weigh the prescribed amount of milnacipran, benzalkonium chloride, sodium carboxymethylcellulose, and disodium edetate, stir and heat to dissolve completely, after cooling, Add deionized water to make the volume to 1000ml, and adjust the pH to 7 with 0.1mol / L hydrochloric acid to obtain milnacipran nasal drops.

Embodiment 3

[0090] Prepare milnacipran nasal drops according to the following ratio:

[0091] Milnacipran

[0092] Sodium carboxymethyl cellulose

[0093] Preparation method: Take 800ml of deionized water, weigh the prescribed amount of milnacipran, sodium chloride, benzalkonium chloride, sodium carboxymethylcellulose, and disodium edetate, stir and heat to dissolve them completely , after cooling, add deionized water to settle to 1000ml, and adjust the pH to 7 with 0.1mol / L hydrochloric acid to obtain milnacipran nasal drops.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
Login to view more

Abstract

The invention provides a Milnacipran composition transferred through noses and brains, which contains a Milnacipran original drug or a pharmaceutically acceptable salt thereof and pharmaceutically necessary auxiliary materials. The composition transferred through the noses and the brains can target to a brain tissue, quickly take effect, reduce adverse reaction of the whole body, and is convenient to use.

Description

technical field [0001] The invention belongs to the field of pharmaceutical preparations, and relates to a milnacipran transnasal-brain transport composition, which is suitable for treating various mild and severe depressions. Background technique [0002] Depression is a common mental disorder. It is mainly characterized by low mood, which is not commensurate with the situation. It can range from gloomy to distraught. In severe cases, hallucinations, delusions and other psychotic symptoms may appear. The cause of the disease is related to the patient's personality, environment, genetics, etc. The pathological changes are prominently manifested as a decrease in the function of central monoamine neurotransmitters. The current drug treatment of depression is mainly used to increase the concentration of 5-hydroxytryptamine (5-hydroxytryptamine) in the central nervous system. HT) and norepinephrine (NE) and other monoamine transmitter levels. [0003] Milnacipran (Milnacipran) ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/135A61K9/08A61K9/12A61K9/14A61K9/16A61K9/70A61K47/34A61K47/38A61P25/24A61K47/10
Inventor 陶涛任锦峰
Owner SHANGHAI INST OF PHARMA IND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap